With great interest, we read the recent article by De Rooij et al.1 and the accompanying editorial.2 The authors showed that functional single-nucleotide polymorphisms within donor genes involved in the lectin complement pathway [mannose-binding lectin 2 (MBL2), ficolin 2, and mannan-binding lectin-associated serine protease 2 (MASP2)] determine the risk of bacterial infections after liver transplantation (LT). Although this is the first study associating single-nucleotide polymorphisms in ficolin 2 and MASP2 with the risk of infection after LT, the value of the donor MBL2 genotype as a risk factor for infection after LT is supported by two other studies.3, 4 However, a fourth study5 found no difference in the overall rate of infections between patients who received liver transplants from donors with insufficient MBL genotypes and those who received liver transplants from donors with sufficient MBL genotypes; although there was a higher incidence of septic shock after transplantation with MBL-insufficient livers. Moreover, the published studies used different ways to stratify MBL genotypes into groups with MBL serum levels predicted to be sufficient or insufficient. Donor YA/YA and YA/XA genotypes result in high serum MBL2 levels, O/O and XA/O genotypes are almost MBL2-deficient, and YA/O and XA/XA genotypes are associated with intermediate MBL2 serum levels after LT.4 Although De Rooij et al. used a strict definition of MBL insufficiency and considered only O/O and XA/O genotypes to be MBL-insufficient, Worthley et al.4 also considered the intermediate XA/XA genotype to be MBL-insufficient, and the two other studies3, 5 also included the second intermediate genotype (YA/O) in the MBL-insufficient group. Therefore, the value of the donor MBL genotype and the method of its interpretation for the early identification of LT patients at risk of infectious complications are not established yet.
We studied the predictive value of donor MBL genotyping for bacterial infections in our own center. The MBL genotypes of 290 donor livers used for orthotopic transplantation between 1987 and 2010 were determined. Notably, this cohort represents the largest single-center cohort of LT patients in which associations between the donor MBL2 genotype and bacterial infections have been analyzed. In three different ways, we categorized donor livers as MBL-sufficient or MBL-insufficient according to the stratification systems used in the cited studies, and we analyzed associations with clinically significant and laboratory-confirmed bacterial infections occurring during the first 3 months after LT by chi-square analysis with Fisher's exact test (Table 1). Thirty-eight percent of LT recipients experienced one or more infectious episodes, and this is comparable to the numbers reported by the previous studies.1, 4, 5 Importantly, none of the three stratifications resulted in a statistically significant association between the donor MBL genotype and clinically significant infections. In addition, when we analyzed associations with site-specific infections, independently of MBL genotype stratification, we observed no significant increases in the risk of intra-abdominal infections or bacteremia in patients who underwent transplantation with MBL-insufficient livers. However, in two of the three types of MBL genotype stratification, significantly more pneumonia was diagnosed in patients who underwent transplantation with MBL-deficient livers.
|Disease Risk||NAFLD Assessment|
|Diabetes||Measure the body mass index, waist circumference, fasting plasma glucose and insulin level, and hemoglobin A1c level.*|
|Perform the 75-g oral glucose tolerance test in NAFLD patients without known diabetes according to standard guidelines (i.e., the American Diabetes Association) to classify their glucose tolerance.|
|Calculate the fasting index of insulin resistance (homeostasis model assessment of insulin resistance), which is associated with the severity of liver disease and has prognostic value in NAFLD.|
|CVD||Assess smoking status, measure blood pressure, plasma total cholesterol, low density lipoprotein(LDL)-cholesterol, high density lipoprotein(HDL) cholesterol and triglycerides.|
|Calculate the CVD risk score (i.e., Framingham risk score).|
|Perform B-mode carotid ultrasonography in patients without diabetes or established CVD who have intermediate CVD risk (Framingham risk score = 6%-20%) to measure carotid intima-media thickening according to recent guidelines6 (optional).|
|Liver-related (end-stage liver disease)||Apply noninvasive tests (i.e., the serum cytokeratin 18 fragment assay, NAFLD fibrosis score, and FibroScan) to screen for the presence of NASH with or without advanced fibrosis.|
|If noninvasive tests yield a high probability of NASH (with or without advanced fibrosis), refer to a gastroenterologist for liver biopsy, the assessment of complications of cirrhosis (hepatic failure, portal hypertension, esophageal varices, and hepatocellular carcinoma), experimental treatments, and tight monitoring.|
|Liver biopsy remains necessary for staging and monitoring the course of liver disease in patients with NASH and if the diagnosis of NAFLD is in doubt.|
In conclusion, this retrospective study indicates that in our center, the donor MBL2 genotype is not helpful in predicting the risk of bacterial infection after LT.